AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12883855 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (Group I, 70 patients)
Number of subjects: 140
Study 12883855 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal drainage (Group II, 70 patients)
Number of subjects: 140
Study 10663618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2
Number of subjects: 110
Study 10663618 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IL-2
Number of subjects: 110
Study 10663618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with idarubicin, ara-C, etoposide
Number of subjects: 110
Study 10663618 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 110
Study 10663618 — intervention group
Group type: COMPARATOR
Intervention: IL-2 treatment arms (high-dose vs low-dose)
Number of subjects: 110
Study 2135254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 400 mg ibuprofen
Number of subjects: 0
Study 2135254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 600 mg ibuprofen with 2 x 6 mg dexamethasone
Number of subjects: 0
Study 2135254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 38965 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 12
Study 38965 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12
Study 38965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 12
Study 30169605 — intervention group
Group type: EXPERIMENTAL
Intervention: HINE E-GEL®
Number of subjects: 67
Study 30169605 — intervention group
Group type: COMPARATOR
Intervention: MEIN®
Number of subjects: 67
Study 28052915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of CDCs
Number of subjects: 41
Study 28052915 — intervention group
Group type: COMPARATOR
Intervention: Late CDC infusion in controls
Number of subjects: 41
Study 28052915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CDC infusion
Number of subjects: 41
Study 26107818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus standard MMT
Number of subjects: 240
Study 26107818 — intervention group
Group type: COMPARATOR
Intervention: Standard MMT
Number of subjects: 240
Study 24406033 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy-enhancing intervention
Number of subjects: 152
Study 24406033 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 152
Study 21751295 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-centered group psychotherapy (MCGP)
Number of subjects: 153
Study 21751295 — intervention group
Group type: COMPARATOR
Intervention: Supportive group psychotherapy (SGP)
Number of subjects: 153
Study 19491860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose with EPO
Number of subjects: 88
Study 19491860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose without EPO
Number of subjects: 88
Study 17146695 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-intensity (CI) cycling
Number of subjects: 10
Study 17146695 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely chosen intensity (FCI) cycling
Number of subjects: 10
Study 17146695 — intervention group
Group type: COMPARATOR
Intervention: Variable-intensity (VI) cycling
Number of subjects: 10
Study 16368038 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate 150 mg
Number of subjects: 342
Study 16368038 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly alendronate 70 mg
Number of subjects: 342
Study 16368038 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate
Number of subjects: 342
Study 16368038 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly alendronate
Number of subjects: 342
Study 11952431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (R) administered in incremental dosages (0.1-0.25-0.5 microg/kg/min)
Number of subjects: 74
Study 11952431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 74
Study 11952431 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (F) 1.5 microg/kg and midazolam (M) titrated between 1 and 10 mg
Number of subjects: 74
Study 9467551 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold dose plus 1/2 ampoule of FSH
Number of subjects: 23
Study 9467551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ampoule above the threshold dose of FSH
Number of subjects: 23
Study 9467551 — intervention group
Group type: COMPARATOR
Intervention: Threshold dose of FSH
Number of subjects: 23
Study 9467551 — intervention group
Group type: COMPARATOR
Intervention: FSH level increase above the threshold
Number of subjects: 23
Study 8699040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 96
Study 8699040 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous infusion of oxytocin
Number of subjects: 96
Study 2550167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (240 mg per day, increased weekly for 4 weeks)
Number of subjects: 10
Study 2550167 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg per day, increased weekly for 4 weeks)
Number of subjects: 10
Study 2550167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6457170 — intervention group
Group type: EXPERIMENTAL
Intervention: 6059-S
Number of subjects: 16
Study 6457170 — intervention group
Group type: COMPARATOR
Intervention: ABPC (2 g)
Number of subjects: 16
Study 6457170 — intervention group
Group type: COMPARATOR
Intervention: SBPC
Number of subjects: 16
Study 30935548 — intervention group
Group type: EXPERIMENTAL
Intervention: Purslane cream (2% w/w)
Number of subjects: 86
Study 30935548 — intervention group
Group type: COMPARATOR
Intervention: Lanolin ointment
Number of subjects: 86
Study 28734858 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-grass pollen tablet
Number of subjects: 2512
Study 28734858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2512
Study 26098833 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinlida (9 g) TID for 12 weeks
Number of subjects: 186
Study 26098833 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID for 12 weeks
Number of subjects: 186
Study 24846373 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated diagnostics (ID) algorithm
Number of subjects: 1224
Study 22417212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei F19 (LF19) 10^8 colony forming units per serving
Number of subjects: 179
Study 22417212 — intervention group
Group type: COMPARATOR
Intervention: Cereals without LF19 (placebo)
Number of subjects: 179
Study 20391059 — intervention group
Group type: EXPERIMENTAL
Intervention: SWF Intervention
Number of subjects: 806
Study 20391059 — intervention group
Group type: COMPARATOR
Intervention: NIDA Standard Intervention
Number of subjects: 806
Study 18416983 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tubes used after primary EN‐DCR
Number of subjects: 42
Study 18416983 — intervention group
Group type: COMPARATOR
Intervention: No silicone tubes used after primary EN‐DCR
Number of subjects: 42
Study 15756155 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 36
Study 15756155 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 36
Study 12175135 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDLINE search methodologies
Number of subjects: 602
Study 12175135 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly publication rate
Number of subjects: 602
Study 10438255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy patients in reversal reaction
Number of subjects: 24
Study 10438255 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy Ethiopians)
Number of subjects: 24
Study 10438255 — intervention group
Group type: COMPARATOR
Intervention: Leprosy patients not in reversal reaction
Number of subjects: 24
Study 7752258 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate (CaCO3) supplements (1.5 g) three times a day for 12 weeks
Number of subjects: 30
Study 7752258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose and starch) three times a day for 12 weeks
Number of subjects: 30
Study 1703920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin tape (5 mg) and ibopamine (100 mg)
Number of subjects: 15
Study 1703920 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin tape (5 mg) and nifedipine (10 mg)
Number of subjects: 15
Study 6958484 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 0
Study 6958484 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (100 micrograms daily)
Number of subjects: 0
Study 6958484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31745073 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported alcohol consumption
Number of subjects: 0
Study 31745073 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype at rs1229984
Number of subjects: 0
Study 28671332 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine intervention
Number of subjects: 0
Study 25702819 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*6/*6 genotype
Number of subjects: 49
Study 25702819 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*1/*6 genotype
Number of subjects: 49
Study 25702819 — intervention group
Group type: COMPARATOR
Intervention: CYP2B6*1/*1 genotype
Number of subjects: 49
Study 25702819 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*6 genotype
Number of subjects: 49
Study 25702819 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 49
Study 25702819 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6*6 genotype and age
Number of subjects: 49
Study 23419134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg orally daily
Number of subjects: 59
Study 23419134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg orally daily + Prednisone 10 mg daily
Number of subjects: 59
Study 21953407 — intervention group
Group type: EXPERIMENTAL
Intervention: NP/CHW intervention (n=261)
Number of subjects: 525
Study 21953407 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) (n=264)
Number of subjects: 525
Study 19728196 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI + spacer
Number of subjects: 303
Study 19728196 — intervention group
Group type: COMPARATOR
Intervention: MDI alone
Number of subjects: 303
Study 17942470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 4 months
Number of subjects: 200
Study 17942470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline for 4 months
Number of subjects: 200
Study 17942470 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 200
Study 17942470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 200
Study 17942470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 17942470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 15477504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment (2-g/kg loading dose, boosters of 0.4 g/kg every 6 weeks for 1 year)
Number of subjects: 91
Study 15477504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment
Number of subjects: 91
Study 15477504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 11825312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study 11825312 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 0
Study 11825312 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of platelet aggregation (including nitric oxide from L-arginine or glyceryl trinitrate) and anticoagulants (low molecular weight heparin, defibrotide)
Number of subjects: 0
Study 11825312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of prostaglandins (PGs) PGE1 and PGI2
Number of subjects: 0
Study 11825312 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine and basic fibroblast growth factor (bFGF)
Number of subjects: 0
Study 9884849 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelographic post‐tetanic count at the great toe
Number of subjects: 24
Study 9884849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical post‐tetanic count at the great toe
Number of subjects: 24
Study 9884849 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelographic train‐of‐four ratios at the great toe
Number of subjects: 24
Study 9884849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical train‐of‐four ratios at the great toe
Number of subjects: 24
Study 8172381 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) applied every eight hours until disappearance of inflammation signs.
Number of subjects: 21
Study 8172381 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied every eight hours until disappearance of inflammation signs.
Number of subjects: 21
Study 8172381 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 21
Study 8172381 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 21
Study 3278754 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid (13-CRA, 100 mg/m2)
Number of subjects: 68
Study 3278754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 3278754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (13-CRA and placebo)
Number of subjects: 68
Study 3278754 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid (13-CRA)
Number of subjects: 68
Study 31925721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg daily)
Number of subjects: 82
Study 31925721 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (60 mg daily)
Number of subjects: 82
Study 30128934 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet-rich plasma (LP-PRP) injection
Number of subjects: 98
Study 30128934 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid injection
Number of subjects: 98
Study 30128934 — intervention group
Group type: COMPARATOR
Intervention: NSAID treatment
Number of subjects: 98
Study 28536030 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-TT
Number of subjects: 4009
Study 28536030 — intervention group
Group type: COMPARATOR
Intervention: Hib-TT control
Number of subjects: 4009
Study 28536030 — intervention group
Group type: COMPARATOR
Intervention: Combination Hib-TT vaccine
Number of subjects: 4009
Study 26301756 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised-CBT (C-CBT)
Number of subjects: 112
Study 26301756 — intervention group
Group type: COMPARATOR
Intervention: Waiting List
Number of subjects: 112
Study 23996468 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI-NBI
Number of subjects: 64
Study 23996468 — intervention group
Group type: COMPARATOR
Intervention: WLE
Number of subjects: 64
Study 21916529 — intervention group
Group type: EXPERIMENTAL
Intervention: FT (FlexTouch*)
Number of subjects: 160
Study 18845963 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day accelerometry
Number of subjects: 951
Study 18845963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 951
Study 16023065 — intervention group
Group type: EXPERIMENTAL
Intervention: Technolas 217A
Number of subjects: 30
Study 16023065 — intervention group
Group type: COMPARATOR
Intervention: VISX S3
Number of subjects: 30
Study 12219853 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-identification task with situational constraints (easy task)
Number of subjects: 0
Study 12219853 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-identification task with situational constraints (difficult task)
Number of subjects: 0
Study 12219853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional-inference task (easy task)
Number of subjects: 0
Study 12219853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional-inference task (difficult task)
Number of subjects: 0
Study 10334399 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgment of Line Orientation Test
Number of subjects: 32
Study 10334399 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial Recognition Test
Number of subjects: 32
Study 10334399 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgment of Line Orientation Test and Facial Recognition Test
Number of subjects: 32
Study 9101886 — intervention group
Group type: EXPERIMENTAL
Intervention: Piggy-back OLT
Number of subjects: 31
Study 9101886 — intervention group
Group type: COMPARATOR
Intervention: Standard OLT
Number of subjects: 31
Study 1919317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1:80,000
Number of subjects: 30
Study 1919317 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 7118100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulltime comprehensive rehabilitation program
Number of subjects: 102
Study 7118100 — intervention group
Group type: COMPARATOR
Intervention: Part-time supportive treatment program
Number of subjects: 102
Study 30399035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay worker administered combination intervention (individualized health education, retention/adherence support, appointment reminders, missed visit tracking)
Number of subjects: 340
Study 30399035 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 340
Study 30399035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and SOC
Number of subjects: 340
Study 30463598 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise programme consisting of 30 min HIIT (30 s 100% peak power output/30 s passive recovery) on the arm crank ergometer and 15 min of upper body circuit resistance training, 2 sessions per week.
Number of subjects: 30
Study 30463598 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise programme
Number of subjects: 30
Study 30463598 — intervention group
Group type: COMPARATOR
Intervention: usual care (medical treatment)
Number of subjects: 30
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection intervention
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen use
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip balm use
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-brimmed hats use
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeved shirts use
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pants use
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunglasses use
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Shade use
Number of subjects: 340
Study 27067306 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting time outdoors
Number of subjects: 340
Study 24467336 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic assessment (TA)
Number of subjects: 74
Study 24467336 — intervention group
Group type: COMPARATOR
Intervention: Structured goal‐focused pretreatment intervention (GFPTI)
Number of subjects: 74
Study 21749169 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride
Number of subjects: 51
Study 21749169 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate
Number of subjects: 51
Study 21749169 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% povidone‐iodine
Number of subjects: 51
Study 21749169 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 20232572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg daily
Number of subjects: 0
Study 20232572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17047171 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH (0.1 mg/kg/d for 3 weeks, then 0.1 mg/kg 3 days a week for 8 weeks)
Number of subjects: 0
Study 17047171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous saline)
Number of subjects: 0
Study 14609147 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS administration with resistance training
Number of subjects: 32
Study 14609147 — intervention group
Group type: COMPARATOR
Intervention: Control group (resistance trained)
Number of subjects: 32
Study 11029341 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV + ET
Number of subjects: 45
Study 11029341 — intervention group
Group type: COMPARATOR
Intervention: ET
Number of subjects: 45
Study 8979662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydroxyamphetamine plus 0.25% tropicamide (Paremyd)
Number of subjects: 60
Study 8979662 — intervention group
Group type: COMPARATOR
Intervention: 0.5% tropicamide combined with 2.5% phenylephrine (TP)
Number of subjects: 60
Study 1426384 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsied group (embryo biopsy on day 2 after insemination)
Number of subjects: 129
Study 3998786 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions during definitive surgical therapy
Number of subjects: 156
Study 3998786 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusions during definitive surgical therapy
Number of subjects: 156
Study 3998786 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions in patients receiving chemotherapy
Number of subjects: 156
Study 3998786 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions in patients with large tumors (greater than 150 mL)
Number of subjects: 156
Study 31059282 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G4® or G5®
Number of subjects: 17
Study 31059282 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG) using OmniPod® Personal Diabetes Manager
Number of subjects: 17
Study 31059282 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 17